NIH Funding Opportunities
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 28 min 10 sec ago
Small Research Grant Program for the Next Generation of Clinical Researchers in Alzheimer's Disease (AD) and Alzheimers Disease Related Dementias (ADRD) Research (R03 Clinical Trial Optional)
Funding Opportunity RFA-AG-19-002 from the NIH Guide for Grants and Contracts. This Small Research Grant Program supports important and innovative research in areas in which more scientific investigation is needed to improve the prevention, diagnosis, treatment and care for Alzheimer's disease and related dementias. The program seeks to stimulate the next generation of researchers in the United States to pursue research and academic careers in neurosciences, Alzheimer's disease and healthy brain aging.
Funding Opportunity RFA-FD-18-022 from the NIH Guide for Grants and Contracts. The Cooperative Agreement announced in this FOA represents the continuation and further refinement as well as expansion of well-established collaborations between WHO and FDA, through OIP, in support of data-driven and science-based public health, science-based and research strategies and approaches that align well with FDA domestic and global goals. This cooperative agreement is expected to contribute to the knowledge base of the current regulatory efforts in support of food and medical products safety and quality globally and address specific challenges and fill gaps in the global efforts to ensure said safety and quality of such products. Relevant strategies include: 1) developing global norms and standards; 2) articulating evidence-based and science-based policy options, including those relating to regulatory systems performance; and 3) providing technical support to national regulatory authorities and governments through systems strengthening, research, public health and scientific efforts.
Notice of Availability of Administrative Supplements for Secondary Analysis of Existing Datasets within the Rare Diseases Clinical Research Network (RDCRN) to Explore Outcomes Relevant to Rare Diseases
Notice NOT-TR-18-019 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-ES-18-006 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to further the development of Advanced Technology Training (ATT) products for the health and safety training of hazardous materials (HAZMAT) workers; skilled support personnel; emergency responders in biosafety response, infectious disease training and cleanup; emergency responders in disasters and resiliency training; and for ATT tools to assist in research into the acute and long-term health effects of environmental disasters. ATT as defined by the Worker Training Program (WTP) includes, but is not limited to, online training, virtual reality, and serious gaming, which complement all aspects of training from development to evaluation including advance technologies that enhance, supplement, improve, and provide health and safety training for hazardous materials workers. These products must complement the goals and objectives of the WTP http://www.niehs.nih.gov/careers/hazmat/about_wetp/. The major objective of the NIEHS WTP is to prevent work related harm by assisting in the training of workers in how best to protect themselves and their communities from exposure to hazardous materials. The financial support for this initiative comes directly from NIEHS Worker Education and Training Branch SBIR funds.
Funding Opportunity RFA-AI-18-015 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications that will advance understanding of vaccine regimens and immune responses that sustainably suppress virus in HIV-infected individuals. The FOA will support small, multi-arm, comparative clinical trials designed to identify correlations between levels of induced immune response and HIV virologic control. Vaccines may be combined with adjuvants and/or other modifiers of the immune response to HIV.
Cooperative Agreement to Support Regulatory Research Related to the 2018 Prescription Drug User Fee Act and the 21st Century Cures Act
Funding Opportunity RFA-FD-18-013 from the NIH Guide for Grants and Contracts. The primary objective of this effort is to provide supporting research, identify key issues, and convene appropriate subject matter experts to help inform major initiatives for process improvement and regulatory science related to FDA commitments under the 2018 reauthorization of the Prescription Drug User Fee Act (PDUFA VI) and the 21st Century Cures Act legislation.
Update in Funds Application Due Date(s) and Expiration Date Sections of RFA-FD-08-019 - Formulation drug product quality attributes in dermal physiologically-based pharmacokinetic models for topical dermatological drug products and transdermal...
Notice NOT-FD-18-010 from the NIH Guide for Grants and Contracts
Update in Funds Available and Anticipated Number of Awards , Award Budget and Award Project Period Sections of RFA-FD-08-018 - Development of a virtual bioequivalence trial simulation platform that integrates population pharmacokinetic modeling...
Notice NOT-FD-18-009 from the NIH Guide for Grants and Contracts
Notice NOT-AG-18-011 from the NIH Guide for Grants and Contracts
NIAID Interest in Administrative Supplements to Address the Research Needed to Develop a Universal Influenza Vaccine
Notice NOT-AI-18-030 from the NIH Guide for Grants and Contracts
Presolicitation Notice: Request for Proposals (RFP) N01CN77019-18 "PREVENT Cancer Preclinical Drug Development Program: Preclinical Services for Biopharmaceutical Product Development and Manufacturing, Toxicology and Pharmacology Testing"
Notice NOT-CA-18-070 from the NIH Guide for Grants and Contracts
Notice of Correction to Award Information in PAR-18-247 Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R21 Clinical Trial Optional)"
Notice NOT-CA-18-065 from the NIH Guide for Grants and Contracts
Notice of Correction to Award Information in PAR-18-246 Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01 Clinical Trial Optional)"
Notice NOT-CA-18-064 from the NIH Guide for Grants and Contracts
Notice to Extend the Expiration Date and Change Receipt Dates for PAR-16-458 "NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32)"
Notice NOT-NS-18-061 from the NIH Guide for Grants and Contracts
Notice of Change in Eligible Organizations in PA-18-748 Research Supplements to Promote Data Sharing in Cancer Epidemiology Studies (Admin Supp Clinical Trial Not Allowed)" to Allow Foreign Institutions.
Notice NOT-CA-18-069 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-RM-18-007 from the NIH Guide for Grants and Contracts. The NIH Directors Pioneer Award supports individual scientists of exceptional creativity who propose highly innovative and potentially transformative approaches to major challenges in the biomedical or behavioral sciences towards the goal of enhancing human health. Applications from individuals with diverse backgrounds and in any topic relevant to the broad mission of NIH are welcome. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigators research program or elsewhere. The NIH Directors Pioneer Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund.
Notice of NICHD Participation in NOT-AG-18-008 "Alzheimer's Disease and its related Dementias (AD/ADRD)-focused Administrative supplements for NIH grants that are not focused on Alzheimer's disease"
Notice NOT-HD-18-010 from the NIH Guide for Grants and Contracts
Notice of Change of Application Due Date to PAR-18-245 "Limited Competition: Exploratory CTSA Collaborative Innovation Awards (R21)"
Notice NOT-TR-18-024 from the NIH Guide for Grants and Contracts
Notice of Change to Application Due Date to PAR-18-244 "Collaborative Innovation Award, Clinical and Translational Science Award (CTSA) Program (U01)"
Notice NOT-TR-18-023 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-18-016 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support research on the development and validation of innovative strategies to deliver anti-HIV gene therapies efficiently to specific target cells in vivo.
NIH Funding Opportunities
- Request for Information (RFI): Strategies for Enhancing Postdoctoral Career Transitions to Promote Faculty Diversity
- Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R41/R42 - Clinical Trial Optional)
- Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R43/R44 - Clinical Trial Optional)
- Notice for the All of Us Research Program Genome Centers (OT2) Funding Announcement and Informational Webinar
- Biomarkers Discovery In Parkinsonism (U01 Clinical Trial Optional)